US Stock MarketDetailed Quotes

Oramed Pharmaceuticals (ORMP)

Watchlist
  • 3.880
  • +0.020+0.52%
Close Apr 17 16:00 ET
  • 3.900
  • +0.020+0.52%
Post 20:01 ET
156.93MMarket Cap2.59P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Oramed Pharmaceuticals (ORMP) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
2M
0
0
0
2M
0
0
0
0
0
Operating revenue
--2M
--0
--0
--0
--2M
--0
--0
--0
--0
--0
Cost of revenue
1.99M
0
0
0
1.99M
0
0
0
0
0
Gross profit
13K
0
0
0
13K
0
0
0
0
0
Operating expense
18.15%15.1M
57.77%5.67M
-21.43%2.43M
-20.61%2.49M
52.36%4.51M
-25.30%12.78M
-7.27%3.6M
6.77%3.09M
-29.79%3.14M
-49.57%2.96M
Selling and administrative expenses
35.05%8.72M
72.63%3.68M
50.41%1.27M
-14.06%1.46M
29.39%2.31M
-20.66%6.46M
1.09%2.13M
-56.25%847K
-35.97%1.69M
23.22%1.78M
-Selling and marketing expense
----
----
----
----
----
--0
--0
--0
--0
--0
-General and administrative expense
35.05%8.72M
72.63%3.68M
50.41%1.27M
-14.06%1.46M
29.39%2.31M
-23.36%6.46M
1.09%2.13M
-67.41%847K
-30.95%1.69M
41.17%1.78M
Research and development costs
0.90%6.38M
36.07%1.99M
-48.57%1.15M
-28.29%1.03M
87.11%2.21M
-29.51%6.32M
-17.27%1.46M
134.27%2.24M
-20.81%1.44M
-73.37%1.18M
Operating profit
-18.05%-15.09M
-57.77%-5.67M
21.43%-2.43M
20.61%-2.49M
-51.92%-4.5M
18.95%-12.78M
7.27%-3.6M
-6.77%-3.09M
17.30%-3.14M
43.13%-2.96M
Net non-operating interest income expense
-56.93%1.77M
-6,979.60%-72.51M
498.64%61.47M
9.97%15.37M
-156.90%-2.56M
-10.59%4.1M
16.46%1.05M
-3,843.73%-15.42M
463.88%13.97M
181.53%4.5M
Non-operating interest income
-52.38%2.37M
----
----
7.95%15.37M
----
-39.00%4.98M
-70.05%1.1M
----
474.41%14.23M
218.60%5.09M
Non-operating interest expense
--0
--0
--0
--0
332.09%2.56M
-58.12%853K
--0
--0
--261K
--592K
Total other finance cost
2,144.44%606K
1,805.93%74.88M
-498.64%-61.47M
----
----
-98.25%27K
--3.93M
--15.42M
----
----
Other net income (expense)
1,324.04%88.65M
87.98M
408K
257K
-144.52%-7.24M
Gain on sale of security
1,310.81%87.69M
----
----
----
----
-144.52%-7.24M
----
----
----
----
Other non- operating income (expenses)
--958K
--293K
--408K
--257K
----
----
----
----
----
----
Income before tax
573.14%75.32M
200.14%9.8M
421.20%59.45M
21.18%13.13M
-560.10%-7.06M
-412.89%-15.92M
-173.58%-9.78M
-463.61%-18.51M
925.44%10.84M
142.48%1.53M
Income tax
255.26%11.31M
-150.96%-212K
876.35%11.06M
-107.71%-126K
584K
3.18M
416K
1.13M
1.63M
0
Net income
435.11%64.02M
198.14%10.01M
346.35%48.39M
44.07%13.26M
-598.17%-7.64M
-475.45%-19.1M
-176.71%-10.2M
-498.11%-19.64M
800.99%9.2M
142.48%1.53M
Net income continuous Operations
435.11%64.02M
198.14%10.01M
346.35%48.39M
44.07%13.26M
-598.17%-7.64M
-475.45%-19.1M
-176.71%-10.2M
-498.11%-19.64M
800.99%9.2M
142.48%1.53M
Minority interest income
20.93%-34K
0
73.91%-6K
-250.00%-28K
0
90.16%-43K
75.00%-10K
62.90%-23K
93.28%-8K
99.07%-2K
Net income attributable to the parent company
436.04%64.05M
198.23%10.01M
346.67%48.4M
44.25%13.29M
-597.53%-7.64M
-444.98%-19.06M
-176.40%-10.19M
-508.91%-19.62M
871.52%9.21M
145.24%1.54M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
436.04%64.05M
198.23%10.01M
346.67%48.4M
44.25%13.29M
-597.53%-7.64M
-444.98%-19.06M
-176.40%-10.19M
-508.91%-19.62M
871.52%9.21M
145.24%1.54M
Basic earnings per share
418.75%1.53
188.46%0.23
341.67%1.16
45.45%0.32
-575.00%-0.19
-442.86%-0.48
-178.79%-0.26
-500.00%-0.48
833.33%0.22
150.00%0.04
Diluted earnings per share
412.50%1.5
188.46%0.23
335.42%1.13
40.91%0.31
-575.00%-0.19
-442.86%-0.48
-178.79%-0.26
-500.00%-0.48
833.33%0.22
150.00%0.04
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 2M0002M00000
Operating revenue --2M--0--0--0--2M--0--0--0--0--0
Cost of revenue 1.99M0001.99M00000
Gross profit 13K00013K00000
Operating expense 18.15%15.1M57.77%5.67M-21.43%2.43M-20.61%2.49M52.36%4.51M-25.30%12.78M-7.27%3.6M6.77%3.09M-29.79%3.14M-49.57%2.96M
Selling and administrative expenses 35.05%8.72M72.63%3.68M50.41%1.27M-14.06%1.46M29.39%2.31M-20.66%6.46M1.09%2.13M-56.25%847K-35.97%1.69M23.22%1.78M
-Selling and marketing expense ----------------------0--0--0--0--0
-General and administrative expense 35.05%8.72M72.63%3.68M50.41%1.27M-14.06%1.46M29.39%2.31M-23.36%6.46M1.09%2.13M-67.41%847K-30.95%1.69M41.17%1.78M
Research and development costs 0.90%6.38M36.07%1.99M-48.57%1.15M-28.29%1.03M87.11%2.21M-29.51%6.32M-17.27%1.46M134.27%2.24M-20.81%1.44M-73.37%1.18M
Operating profit -18.05%-15.09M-57.77%-5.67M21.43%-2.43M20.61%-2.49M-51.92%-4.5M18.95%-12.78M7.27%-3.6M-6.77%-3.09M17.30%-3.14M43.13%-2.96M
Net non-operating interest income expense -56.93%1.77M-6,979.60%-72.51M498.64%61.47M9.97%15.37M-156.90%-2.56M-10.59%4.1M16.46%1.05M-3,843.73%-15.42M463.88%13.97M181.53%4.5M
Non-operating interest income -52.38%2.37M--------7.95%15.37M-----39.00%4.98M-70.05%1.1M----474.41%14.23M218.60%5.09M
Non-operating interest expense --0--0--0--0332.09%2.56M-58.12%853K--0--0--261K--592K
Total other finance cost 2,144.44%606K1,805.93%74.88M-498.64%-61.47M---------98.25%27K--3.93M--15.42M--------
Other net income (expense) 1,324.04%88.65M87.98M408K257K-144.52%-7.24M
Gain on sale of security 1,310.81%87.69M-----------------144.52%-7.24M----------------
Other non- operating income (expenses) --958K--293K--408K--257K------------------------
Income before tax 573.14%75.32M200.14%9.8M421.20%59.45M21.18%13.13M-560.10%-7.06M-412.89%-15.92M-173.58%-9.78M-463.61%-18.51M925.44%10.84M142.48%1.53M
Income tax 255.26%11.31M-150.96%-212K876.35%11.06M-107.71%-126K584K3.18M416K1.13M1.63M0
Net income 435.11%64.02M198.14%10.01M346.35%48.39M44.07%13.26M-598.17%-7.64M-475.45%-19.1M-176.71%-10.2M-498.11%-19.64M800.99%9.2M142.48%1.53M
Net income continuous Operations 435.11%64.02M198.14%10.01M346.35%48.39M44.07%13.26M-598.17%-7.64M-475.45%-19.1M-176.71%-10.2M-498.11%-19.64M800.99%9.2M142.48%1.53M
Minority interest income 20.93%-34K073.91%-6K-250.00%-28K090.16%-43K75.00%-10K62.90%-23K93.28%-8K99.07%-2K
Net income attributable to the parent company 436.04%64.05M198.23%10.01M346.67%48.4M44.25%13.29M-597.53%-7.64M-444.98%-19.06M-176.40%-10.19M-508.91%-19.62M871.52%9.21M145.24%1.54M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 436.04%64.05M198.23%10.01M346.67%48.4M44.25%13.29M-597.53%-7.64M-444.98%-19.06M-176.40%-10.19M-508.91%-19.62M871.52%9.21M145.24%1.54M
Basic earnings per share 418.75%1.53188.46%0.23341.67%1.1645.45%0.32-575.00%-0.19-442.86%-0.48-178.79%-0.26-500.00%-0.48833.33%0.22150.00%0.04
Diluted earnings per share 412.50%1.5188.46%0.23335.42%1.1340.91%0.31-575.00%-0.19-442.86%-0.48-178.79%-0.26-500.00%-0.48833.33%0.22150.00%0.04
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +14.09%
Sample Name
Sample Code
 +3.93%
Sample Name
Sample Code
 +2.06%
4
United States Oil Fund LP
USO
-1.12%
5
United States Gasoline Fund Lp
UGA
-2.10%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.28%
Sample Name
Sample Code
 +20.52%
Sample Name
Sample Code
 +19.71%
4
Zai Lab
ZLAB
+16.97%
5
Legend Biotech
LEGN
+16.57%
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 17, the Iranian foreign minister announced the opening of the Strait of Hormuz to merchant ships, and Trump immediately posted a me Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -